BBA
CRSP icon

Baker Bros. Advisors’s CRISPR Therapeutics CRSP Stock Holding History

Baker Bros. Advisors’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-654,099
Closed -$22.3M – 91
2025
Q1 		$22.3M Sell
654,099
-653,912
-50% -$27.7M 0.25% 33
2024
Q4 		$51.5M Buy
1,308,011
+464,936
+55% +$22M 0.55% 24
2024
Q3 		$39.6M Buy
843,075
+743,075
+743% +$37.7M 0.41% 28
2024
Q2 		$5.4M Buy
+100,000
New +$5.78M 0.07% 63

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baker Bros. Advisors's CRSP Position: Q2 2025 in Review

Baker Bros. Advisors sold out of CRISPR Therapeutics (CRSP) in Q2 2025, closing a stake of 654,099 shares — an estimated $22.3M sold.

Baker Bros. Advisors first reported a position in CRSP in Q2 2024 and held it in 4 quarters. The position peaked at $51.5M in Q4 2024. 433 funds tracked by Wall St. Rank hold CRSP as of Q2 2025.

  • Baker Bros. Advisors reported no remaining CRISPR Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Baker Bros. Advisors sold 654,099 CRISPR Therapeutics shares in Q2 2025, an estimated $22.3M.
  • Baker Bros. Advisors first reported a position in CRISPR Therapeutics in Q2 2024 and held it in 4 quarters.
  • Baker Bros. Advisors's CRISPR Therapeutics position peaked at $51.5M in Q4 2024.
  • 433 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2025.

Based on Baker Bros. Advisors's 13F filing for Q2 2025, filed 14 Aug 2025.